Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: A pilot study

Japanese Journal of Clinical Oncology

Volumn 31, Issue 8, 2001, Pages 395-398

  Oya, Masatoshi ^a   Akiyama, Yoshitake ^a   Okuyama, Takashi ^a   Ishikawa, Hiroshi ^a  

^a DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Outpatient setting; Paclitaxel; Recurrent gynecological tumors; Salvage therapy; Weekly infusion

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; PEPLEOMYCIN; PLATINUM DERIVATIVE; VINBLASTINE;

ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG INFUSION; DRUG SAFETY; EVALUATION; FATIGUE; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; PILOT STUDY; PREMEDICATION; QUALITY OF LIFE; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE;

AMBULATORY CARE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PILOT PROJECTS; QUALITY OF LIFE; SALVAGE THERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 0034792150     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Phase II trial of paclitaxel with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecological Oncology Group Study
2. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103
3. Paclitaxel has moderate activity in squamous cervical cancer: A Gynecological Oncology Group Study
4. Taxol is active in platinum-resistant endometrial adenocarcinoma
5. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion
6. Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: Brief report
7. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
8. Paclitaxel (taxol): Phase I/II trial comparing 1 hour infusion schedules
9. A feasibility study of 1 h paclitaxel infusion in patients with solid tumors
10. Salvage weekly paclitaxel in recurrent ovarian cancer
11. Schedule and dose intensified paclitaxel as weekly 1 h infusion in pretreated solid tumors: Results of a phase I/II trial
12. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
13. Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer
14. An updated analysis of a randomized study of single agent paclitaxel (P) given weekly vs every 3 weeks to patients (Pts) with ovarian cancer (OC) treated with prior platinum therapy
15. Dose-dense therapy with weekly 1 h paclitaxel infusion in the treatment of metastatic breast cancer
16. Short course intravenous prophylaxis for paclitaxel related hypersensitivity reactions